Literature DB >> 848800

Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma).

R Salerni, G P Rodnan, D F Leon, J A Shaver.   

Abstract

Severe pulmonary hypertension without pulmonary fibrosis occurred in 10 patients with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia), reputedly a benign variant of progressive systemic sclerosis. Time from the initial symptom, Raynaud's phenomenon, to the recognition of pulmonary hypertension was as long as 40 years. Pulmonary hypertension and increased pulmonary vascular resistance was shown in all patients. Autopsy examination in three of six deaths attributable to pulmonary hypertension showed intimal proliferation with myxomatous change in the small- and medium-sized pulmonary arteries similar to changes in the digital arteries of patients with scleroderma and Raynaud's phenomenon, and interlobular renal arteries of those with "scleroderma kidney." It is concluded that the CREST syndrome is not entirely benign but may be complicated, after a long clinical course, by progressive pulmonary vascular obliteration, pulmonary hypertension, and death in the absence of significant pulmonary fibrosis.

Entities:  

Mesh:

Year:  1977        PMID: 848800     DOI: 10.7326/0003-4819-86-4-394

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  31 in total

Review 1.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

Review 3.  Utility of serologic testing in the diagnosis of noninfectious pulmonary disorders.

Authors:  R H White; J A Golden
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

4.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

5.  Severe pulmonary hypertension in a patient with rheumatoid arthritis--response to nifedipine.

Authors:  S G Lehrman; R C Hollander
Journal:  West J Med       Date:  1986-08

6.  Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele.

Authors:  R A Asherson; A G Benbow; C J Speirs; N Jackson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

7.  Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report.

Authors:  E M Yoshida; S R Erb; D N Ostrow; D R Ricci; C H Scudamore; G Fradet
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods.

Authors:  S Majewski; M Błaszczyk; S Jabłonska; L Rudnicka; M Waşik; A Skiendzielewska; B Makieła
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

9.  Primary pulmonary hypertension associated with systemic lupus erythematosus.

Authors:  A Turner; A Samanta; F E Nichol
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

10.  Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension.

Authors:  Silvia Ulrich; Mark R Nicolls; Laima Taraseviciene; Rudolf Speich; Norbert Voelkel
Journal:  Respiration       Date:  2007-11-20       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.